MA46229B1 - Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 - Google Patents
Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2Info
- Publication number
- MA46229B1 MA46229B1 MA46229A MA46229A MA46229B1 MA 46229 B1 MA46229 B1 MA 46229B1 MA 46229 A MA46229 A MA 46229A MA 46229 A MA46229 A MA 46229A MA 46229 B1 MA46229 B1 MA 46229B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- ripk2
- inhibitors
- carboxamide compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La présente invention porte sur des composés de formule (i) : ou leurs sels pharmaceutiquement acceptables, dans laquelle r1, r2, x, y et het sont tels que définis dans la description. L'invention concerne également des compositions pharmaceutiques contenant ces composés, des procédés d'utilisation de ces composés pour traiter différents troubles et maladies, ainsi que des procédés de préparation de ces composés et des intermédiaires utilisés dans ces procédés
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394779P | 2016-09-15 | 2016-09-15 | |
PCT/US2017/050197 WO2018052772A1 (fr) | 2016-09-15 | 2017-09-06 | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46229A MA46229A (fr) | 2019-07-24 |
MA46229B1 true MA46229B1 (fr) | 2020-10-28 |
Family
ID=59901598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46229A MA46229B1 (fr) | 2016-09-15 | 2017-09-06 | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 |
Country Status (32)
Country | Link |
---|---|
US (3) | US10138241B2 (fr) |
EP (1) | EP3512833B1 (fr) |
JP (1) | JP6733050B2 (fr) |
KR (1) | KR102472736B1 (fr) |
CN (1) | CN110023290B (fr) |
AR (1) | AR109650A1 (fr) |
AU (1) | AU2017327539B2 (fr) |
BR (1) | BR112019003320B1 (fr) |
CA (1) | CA3037141A1 (fr) |
CL (1) | CL2019000476A1 (fr) |
CO (1) | CO2019001181A2 (fr) |
CY (1) | CY1123494T1 (fr) |
DK (1) | DK3512833T3 (fr) |
EA (1) | EA038128B1 (fr) |
ES (1) | ES2816003T3 (fr) |
HR (1) | HRP20201494T1 (fr) |
HU (1) | HUE051551T2 (fr) |
IL (1) | IL265062B (fr) |
LT (1) | LT3512833T (fr) |
MA (1) | MA46229B1 (fr) |
MX (1) | MX2019003026A (fr) |
NZ (1) | NZ750416A (fr) |
PE (1) | PE20190979A1 (fr) |
PH (1) | PH12019500497A1 (fr) |
PL (1) | PL3512833T3 (fr) |
PT (1) | PT3512833T (fr) |
RS (1) | RS60729B1 (fr) |
SA (1) | SA519401322B1 (fr) |
SI (1) | SI3512833T1 (fr) |
TW (1) | TWI749062B (fr) |
UA (1) | UA123287C2 (fr) |
WO (1) | WO2018052772A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
WO2018052773A1 (fr) * | 2016-09-15 | 2018-03-22 | Boehringer Ingelheim International Gmbh | Composés de pyridine et de pyrazine en tant qu'inhibiteurs de ripk2 |
KR102472736B1 (ko) | 2016-09-15 | 2022-12-02 | 베링거 인겔하임 인터내셔날 게엠베하 | Ripk2의 저해제로서의 헤테로아릴 카복스아미드 화합물 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
TW202039481A (zh) * | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
TW202102498A (zh) * | 2019-03-22 | 2021-01-16 | 日商武田藥品工業股份有限公司 | 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物 |
WO2023239941A1 (fr) | 2022-06-10 | 2023-12-14 | Interline Therapeutics Inc. | Dérivés d'imidazo(1,2-a)pyridine utilisés en tant qu'inhibiteurs de ripk2 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2385041B1 (fr) | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Composés de pyrazole-amines utilés en tant qu'inhibiteurs de kinase |
AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
BRPI0712795A2 (pt) | 2006-07-07 | 2012-09-04 | Boehringer Ingelheim Int | derivados de heteroarila substituìdos com fenila e uso dos mesmos como agentes antitumorais |
CN101528717B (zh) | 2006-11-09 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | 噻唑和*唑-取代的芳基酰胺类化合物 |
CA2716385A1 (fr) | 2008-02-27 | 2009-09-03 | Lars Thore Burgdorf | Derives d'heteroaryl-carboxamides utilises pour le traitement du diabete |
CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
US20130023532A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Indazolyl-pyrimidines as kinase inhibitors |
EP2552208A4 (fr) * | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | Imidazolyl-imidazoles en tant qu'inhibiteurs de kinase |
UY34863A (es) | 2012-06-19 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Antagonistas de iap |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TW201427668A (zh) | 2012-11-20 | 2014-07-16 | Celgene Avilomics Res Inc | 治療和布魯頓(bruton’s)酪胺酸激酶相關之疾病或失調的方法 |
HUE036065T2 (hu) * | 2013-02-06 | 2018-06-28 | Bayer Cropscience Ag | Halogén-szubsztituált pirazol-származékok mint kártevõirtó szerek |
WO2014145022A1 (fr) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Inhibiteurs hybrides de la nécroptose |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
BR112016017527B1 (pt) | 2014-01-03 | 2021-01-05 | Bayer Animal Health Gmbh | compostos, usos de compostos, composições farmacêuticas, processo para produzir composições e método não terapêutico para controlar pragas |
US10239881B2 (en) * | 2014-10-27 | 2019-03-26 | University Health Network | RIPK2 inhibitors and method of treating cancer with same |
IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
KR102472736B1 (ko) | 2016-09-15 | 2022-12-02 | 베링거 인겔하임 인터내셔날 게엠베하 | Ripk2의 저해제로서의 헤테로아릴 카복스아미드 화합물 |
WO2018052773A1 (fr) | 2016-09-15 | 2018-03-22 | Boehringer Ingelheim International Gmbh | Composés de pyridine et de pyrazine en tant qu'inhibiteurs de ripk2 |
-
2017
- 2017-09-06 KR KR1020197010671A patent/KR102472736B1/ko active IP Right Grant
- 2017-09-06 CN CN201780056054.1A patent/CN110023290B/zh active Active
- 2017-09-06 PE PE2019000500A patent/PE20190979A1/es unknown
- 2017-09-06 WO PCT/US2017/050197 patent/WO2018052772A1/fr unknown
- 2017-09-06 PL PL17768914T patent/PL3512833T3/pl unknown
- 2017-09-06 JP JP2019514206A patent/JP6733050B2/ja active Active
- 2017-09-06 US US15/696,540 patent/US10138241B2/en active Active
- 2017-09-06 AU AU2017327539A patent/AU2017327539B2/en active Active
- 2017-09-06 SI SI201730450T patent/SI3512833T1/sl unknown
- 2017-09-06 ES ES17768914T patent/ES2816003T3/es active Active
- 2017-09-06 MX MX2019003026A patent/MX2019003026A/es unknown
- 2017-09-06 UA UAA201903410A patent/UA123287C2/uk unknown
- 2017-09-06 BR BR112019003320-3A patent/BR112019003320B1/pt active IP Right Grant
- 2017-09-06 LT LTEP17768914.8T patent/LT3512833T/lt unknown
- 2017-09-06 CA CA3037141A patent/CA3037141A1/fr active Pending
- 2017-09-06 MA MA46229A patent/MA46229B1/fr unknown
- 2017-09-06 PT PT177689148T patent/PT3512833T/pt unknown
- 2017-09-06 NZ NZ750416A patent/NZ750416A/en unknown
- 2017-09-06 EA EA201990678A patent/EA038128B1/ru not_active IP Right Cessation
- 2017-09-06 RS RS20201022A patent/RS60729B1/sr unknown
- 2017-09-06 DK DK17768914.8T patent/DK3512833T3/da active
- 2017-09-06 EP EP17768914.8A patent/EP3512833B1/fr active Active
- 2017-09-06 HU HUE17768914A patent/HUE051551T2/hu unknown
- 2017-09-14 AR ARP170102539A patent/AR109650A1/es unknown
- 2017-09-14 TW TW106131512A patent/TWI749062B/zh active
-
2018
- 2018-10-12 US US16/158,407 patent/US11130754B2/en active Active
-
2019
- 2019-02-08 CO CONC2019/0001181A patent/CO2019001181A2/es unknown
- 2019-02-22 CL CL2019000476A patent/CL2019000476A1/es unknown
- 2019-02-26 IL IL265062A patent/IL265062B/en active IP Right Grant
- 2019-03-07 PH PH12019500497A patent/PH12019500497A1/en unknown
- 2019-03-14 SA SA519401322A patent/SA519401322B1/ar unknown
-
2020
- 2020-09-18 HR HRP20201494TT patent/HRP20201494T1/hr unknown
- 2020-10-22 CY CY20201101004T patent/CY1123494T1/el unknown
-
2021
- 2021-08-24 US US17/409,956 patent/US20220081437A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
MA47043B1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
TNSN07022A1 (fr) | Derives de pyridine | |
TN2009000450A1 (fr) | Derives de pyridine | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA49127B1 (fr) | Dérivés d'indole n-substitués | |
MA41179A (fr) | Composés inhibiteurs de parg | |
MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 |